B
모아라이프플러스
142760KOSDAQ56.5 / 100
Reference Date: 2026-10-23
Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure15.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Moalifeplus focuses on biopharmaceutical R&D using proprietary technologies (HumaMAX, MucoMAX), alongside consumer businesses such as health functional foods, cosmetics, and pet care products. Its γ-PGA-based functional ingredients are approved by the Korean FDA and the U.S. FDA, enabling global expansion through partnerships with Swiss companies and overseas exports of skincare brands.
Number of Employees
54people
Average Salary
39.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.34Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-36.73Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
1.91Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼21.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼12.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.1% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (9%, downtrend)
Current 487Won52-week high 1,85052-week low 349
1-month return3.0Point
1m -1.81% (flat)
Volume trend6.0Point
Volume surge
Detailed Disclosure
29 totalPositive 9Neutral 20Negative 0
- Neutral[기재정정]주요사항보고서(주권관련사채권양도결정)2026-10-21
- Neutral[기재정정]주요사항보고서(주권관련사채권양도결정)2026-10-20
- Positive[기재정정]주요사항보고서(유상증자결정)2026-10-19
- Neutral[기재정정]소액공모공시서류(지분증권)2026-10-19
- Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-10-16